Quick Answer
ENDONOVO THERAPEUTICS, INC. reported Gross Profit of $125.4 thousand for the year ending 2022.
- ENDONOVO THERAPEUTICS, INC. showed an increase of +115.7% in Gross Profit from 2021 to 2022.
- This data is from ENDONOVO THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on April 17, 2023.
- XBRL data for this metric is available from 2014 to 2022 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2014: $10.5 thousand | Q3 2014: $4.8 thousand | Q2 2015: $582.00 | Q3 2015: -$400.00 | Q1 2018: $7.0 thousand | Q2 2018: $12.3 thousand | Q3 2018: $17.0 thousand | Q1 2019: $37.2 thousand | Q2 2019: $33.2 thousand | Q3 2019: $45.1 thousand | Q1 2020: $63.4 thousand | Q2 2020: $33.3 thousand | Q3 2020: $39.2 thousand | Q1 2021: $32.2 thousand | Q2 2021: $29.8 thousand | Q3 2021: $4.7 thousand | Q1 2022: $1.6 thousand | Q2 2022: $267.00 | Q3 2022: $6.9 thousand | Q1 2023: $83.5 thousand | Q2 2023: $45.2 thousand | Q3 2023: $693.00.
- Over the full 7 years of available data (2014 to 2022), ENDONOVO THERAPEUTICS, INC.'s Gross Profit has grown by 1,339.8%.
- Historical annual values: Fiscal year 2022: $125.4 thousand | Fiscal year 2021: $58.1 thousand | Fiscal year 2020: $100.4 thousand | Fiscal year 2019: $216.8 thousand | Fiscal year 2018: $70.3 thousand | Fiscal year 2015: $2.1 thousand | Fiscal year 2014: $8.7 thousand.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: